Abstract
Antiaggregant treatment is suitable for all at risk patients with atherothrombosis and its cardiovascular complications. Antiaggregant treatment decreases severe vascular events in at risk patients, myocardial infarctions, non-fatal strokes, transient~ischemic attack, unstable angina, obstructive peripheral vascular disease.
It decreases a risk of embolism caused by atrial fibrillation and a risk of vascular occlusion in other patients at high risk. Antiaggregant treatment should be administered~long-term.
The basis antiaggregant drug is acetylsalicylic acid (ASA) which is commonly used in doses of 75-150 mg daily. ASA is an effective antiaggregant drug with clearly demonstrated beneficial effect on atherothrombotic complications in~cardiovascular disease.
Other substances and drugs with antiaggregant effect inducing their modes of action and indications are reviewed.~